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Abstract
Background: HIV prevention trials are increasingly being conducted in sub-Saharan Africa. Women at risk for HIV are also at
risk of pregnancy. To maximize safety, women agree to avoid pregnancy during trials, yet pregnancies occur. Using data
from the HVTN 503/‘‘Phambili’’ vaccine trial, we report pregnancy incidence during and after the vaccination period and
identify factors, measured at screening, associated with incident pregnancy.
Methods: To enrol in the trial, women agreed and were supported to avoid pregnancy until 1 month after their third and
final vaccination (‘‘vaccination period’’), corresponding to the first 7 months of follow-up. Unsterilized women, pooled
across study arms, were analyzed. Poisson regression compared pregnancy rates during and after the vaccination period.
Cox proportional hazards regression identified associations with first pregnancy.
Results: Among 352 women (median age 23 yrs; median follow-up 1.5 yrs), pregnancy incidence was 9.6/100 women-years
overall and 6.8/100 w-yrs and 11.3/100 w-yrs during and after the vaccination period, respectively [Rate Ratio=0.60 (0.32–
1.14), p=0.10]. In multivariable analysis, pregnancy was reduced among women who: enrolled at sites providing
contraception on-site [HR=0.43, 95% CI (0.22–0.86)]; entered the trial as injectable contraceptive users [HR=0.37 (0.21–
0.67)] or as consistent condom users (trend) [HR=0.54 (0.28–1.04)]. Compared with women with a single partner of HIV-
unknown status, pregnancy rates were increased among women with: a single partner whose status was HIV-negative
[HR=2.34(1.16–4.73)] and; 2 partners both of HIV-unknown status [HR=4.42(1.59–12.29)]. Women with 2 more of these risk
factors: marijuana use, heavy drinking, or use of either during sex, had increased pregnancy incidence [HR=2.66 (1.24–
5.72)].
Conclusions: It is possible to screen South African women for pregnancy risk at trial entry. Providing injectable
contraception for free on-site and supporting consistent condom use may reduce incident pregnancy. Screening should
determine the substance use, partnering, and HIV status of both members of the couple for both pregnancy and HIV
prevention.
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Clinical trials to test effectiveness of HIV preventive methods
are increasingly being conducted in Sub-Saharan Africa where
HIV incidence is high. Women at risk for HIV recruited for
these trials are also often at high risk of pregnancy, yet are asked
to avoid pregnancy whilst on investigational products regardless
of the trial phase, as safety to the unborn child is usually
unknown. In microbicide trials, women are tested for pregnancy
frequently and are taken off study product if they become
pregnant. In vaccine trials, women commit to avoiding
pregnancy during the vaccination period, and the vaccination
schedule is halted if a woman becomes pregnant. Being able to
identify women at higher risk for pregnancy at screening may
enhance participant safety and minimizes time off study product,
which increases trial efficiency [1].
While pregnancy incidence rates were as high as 64/100
woman-years (/100 w-yrs) in early microbicide trials [2,3]
attributed in part to ascertainment bias, rates from recently-
completed trials testing microbicides, the diaphragm and an
HSV-suppression strategy have been lower, ranging from 4.0–
27.1/100 w-yrs [4–8]. Nonetheless, pregnancies still occurred
despite women’s expressed commitment, and need, to avoid
pregnancy during trial participation. Pregnancy risk during
vaccine trials is poorly characterized. Of the two vaccine trials
in sub-Saharan Africa [9,10], one reported on pregnancy, and
found a cumulative pregnancy incidence of 8.7% overall, but
did not report on risk factors [10]. In a large vaccine trial in
Thailand, 4.3% of women became pregnant during the 7-
month vaccination period, but again, risk factors were not
evaluated [11,12].
Factors associated with pregnancy in HIV prevention trials
conducted in sub-Saharan Africa are only now being reported.
In an analysis of multiple trials, use of injectable hormonal
contraception was associated with reduced pregnancy incidence
[8]; while use of oral contraceptive pills (OCPs), method
switching and younger age were commonly associated with
increased incidence [7,8,13]. Lack of convenient availability and
the perception that available contraceptive services are of low
quality have been noted as barriers to contraceptive use among
women participating in an African vaccine trial [10]. The role
of condoms during trials has been mixed. In one study condoms
were associated with reduced pregnancy risk only when condom
use was carefully measured [7], while another found that
condom use at last sex, but not ‘‘condom use’’ generally, was
associated with reduced pregnancy rates [8]. These findings,
along with variations in pregnancy rates between trials, suggest
that pregnancy risk can be modified. It is particularly important
to identify factors that can help African women avoid
pregnancy in vaccine trials as the experimental dose cannot
be readily withdrawn, yet nothing has been reported on risk
factors for incident pregnancy during vaccine trials.
Using data from women who participated in the HVTN 503
‘‘Phambili’’ trial testing an HIV vaccine, we report pregnancy
rates and outcomes during and after the vaccination period, and
identify factors reported at screening that were associated with
incident pregnancy during this trial. We also evaluated associa-
tions of contraception and condom use during the trial with
pregnancy incidence as such use may be modified by trial staff
through counselling and enhanced access. Findings from this
analysis may improve screening and support of women in
minimizing pregnancy during future HIV prevention trials in
sub-Saharan Africa.
Methods
Ethics Statement
This analysis was approved by the ethics boards governing all 5
trial sites, including the University of KwaZulu Natal (2 sites), The
University of Cape Town, The University of the Witwatersrand,
and the Medical University of South Africa, as well as the London
School of Hygiene and Tropical Medicine (statistician, author
KF), the Medicines Control Council of South Africa and the
Genetically Modified Organism Review Committee of the South
African Department of Agriculture.
Study Design
While these data derive from a randomized trial [14], the study
design for this analysis was an observational cohort. Women were
pooled across trial arms as the experimental product was found to
be ineffective against HIV [14,15] and was not hypothesized to
affect fertility.
Sample
Women enrolled in HVTN 503 ‘‘Phambili’’, an HIV vaccine
trial, comprised the source population for this analysis [14].
Participants were recruited at five sites in South Africa: Cape
Town, Durban, Klerksdorp, Soweto and Pretoria. Phambili was a
two-arm, phase IIB, double-blind randomized trial to evaluate the
safety and efficacy of a 3 dose-regimen (given at enrolment, 1 and 6
months) of the clade B Merck adenovirus serotype 5 HIV-1 gag/
pol/nef vaccine. Men and women aged 18 to 35 were eligible for
enrolment. The eligibility criteria for women were being: sexually
active in the 6 months prior to screening, in good health with ALT
levels less than 2.6 times the upper limit of normal range, sero-
negative for HIV1 and 2, and not breastfeeding nor pregnant at
enrolment. All women also had to agree to avoid pregnancy during
thevaccinationperiod,whichencompassedthefirst7monthsoftrial
follow up. After screening, non-sterile women also had to agree to
consistently use at least 2 forms of contraception: 1 hormonal and 1
barrier method until at least 1 month after her third, and final
scheduled, vaccine injection (the ‘‘vaccination period’’). At enrol-
ment women had to provide documentation of hormonal method
useforatleast21 dayspriortoenrolment,whenthefirstvaccinewas
injected.
Detailed exclusion criteria are available elsewhere [14], but
generally persons were excluded if they were immune deficient or
had an auto-immune disease, had ever taken part in an HIV
vaccine trial, had recently (5 to 90 days before enrolment) received
immunosuppressive therapy, blood or immuoglobin, or other
vaccines or allergy treatment. All participants gave written
informed consent, and had to demonstrate their understanding
of trial concepts prior to enrolment.
Analytic Sample
Of the 801 persons enrolled, 360 were women, and 352 were at
risk for pregnancy at enrolment and included in this analysis (n=7
women were surgically sterilized before screening; n=1 was later
determined to be pregnant at enrolment).
Independent Variables
Data on demographics, contraceptive and condom use, sexual
behaviour, sexual partners (numbers, HIV status and risk profile),
substance use, and history of sexually transmitted infection (STI)
were collected via structured, face-to-face interviews by nurses
during the screening period (referred to as screening or baseline
variables). Screening could take place up to 56 days prior to
enrolment, and women had their screening interviews a median of
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in reference to the six months prior, except contraception and
condoms which referred to current use. Use of condoms was asked
in two ways: whether currently being used via a single question,
and through a series of questions about condom use in the 6
months prior, by partner type and whether condom use with that
partner type was consistent or not. Both condom use variables
were examined given mixed evidence on the role of condom use in
pregnancy prevention; each variable was considered separately in
modelling to avoid collinearity.
One site-level variable was considered. Three of the research
sites supplied free hormonal contraception (injectables or the pill),
throughout the trial. At the remaining sites women were referred
to free public sector clinics for injectables or oral contractive pills.
Sites were categorized by whether hormonal contraception was
available on or off site.
Contraceptive, condom use, and partner data were also
collected at 3, 7, 12 and 18 months of follow up, and data from
the latter 3 visits were analysed as they provided non-overlapping
information (questions referred to ‘‘last 6 months’’). We analysed
current condom use (yes/no), consistent condom use, and
hormonal contraception use during the trial. Data on other forms
of protection were too infrequent for analysis. Contraceptive use
during the trial (time-varying variables) was not independent of use
at screening, and therefore the former were not included in
multivariable modelling.
Dependent Variable: Incident Pregnancy
The main outcome variable was first pregnancy during follow
up, whether within or outside the vaccination period. Pregnancies
were measured in 1 of 2 ways: either via a ß-HCG urine
pregnancy test, or by dating the pregnancy from last menstrual
period if a woman reported being, or was clinically noted as,
pregnant. Of the 48 pregnancies observed, 30 (62%) were
confirmed with a urine pregnancy test; 85% (11/13) and 54%
(19/35) of pregnancies were confirmed with a urine test during the
vaccination period, and post-vaccination period, respectively. Date
of incident pregnancy was defined either as 14 days after the last
menstrual period (LMP), or if LMP was unknown, then as the
estimated date of delivery date minus 266 days.
Per Protocol Pregnancy Testing, and Pregnancy
Prevention Counselling
Vaccinations were scheduled to occur at enrolment and months
1 and 6. All women were counselled and supported to avoid
pregnancy during the vaccination period, defined as the period
from enrolment (first vaccine) until 1 month after last vaccination –
or the first 7 months of follow up for each woman. The protocol
specified pregnancy testing before each vaccination was adminis-
tered, and thus pregnancy testing was routinely done during the
vaccination period. After the vaccination period, pregnancy testing
was done if indicated or requested by the participant. The
differential in pregnancy testing during and after the vaccination
period was to avoid administration of the experimental vaccine to
a pregnant woman.
Actual Pregnancy Testing and Pregnancy Prevention
Counselling
Enrolment for this trial started 24 January 2007. Enrolment and
all vaccinations were unexpectedly halted on 19 September 2007
when it became known, through another trial testing the same
product, that the vaccine product under testing was not effective in
preventing HIV or reducing early post-infection viral load. The
Phambili trial was testing the same product as the Step trial
(HVTN 502) [15], which had started several years before and
released its findings of no effect, when enrolment for the Phambili
trial was in its ninth month. The unanticipated cessation of
enrolment and vaccinations for the Phambili trial meant that not
all enrolled received the full course of 3 vaccines and the
vaccination period–the time when pregnancy was to be avoided–
varied in length for each woman depending on when she was
enrolled. Additionally after 19 September pregnancy prevention
messages varied. One site counselled women to adhere to the
initial plan, and to avoid pregnancy until one month after what
would have been her third vaccination (avoid for 7 months). Two
sites counselled women to avoid pregnancy until 1 month after her
last vaccination, whether it was the first, second or third. Two sites
counselled women to avoid pregnancy until they were ready to
have children. All women were supported and counselled to avoid
pregnancy during the vaccination period, and all women received
as-needed contraception counselling (and were provided with
contraception at sites with that facility) throughout the trial.
Pregnancy Rates and Outcomes Stratified by Vaccination
Period
Given the varied pregnancy prevention messages after vaccina-
tions were stopped, we considered several ways of defining the
vaccination period. Upon further examination of the frequency of
pregnancy testing, and despite variations in pregnancy counselling,
pregnancy testing remained largely in line with the protocol: 87%
of women were tested for pregnancy at the end of their initially-
scheduled vaccination period, and pregnancy testing became less
frequent thereafter. Therefore we defined the vaccination period
as the first 7 months of follow up. We calculated pregnancy rates
stratified by the vaccination period (during versus after), with the
expectation that observed pregnancy rates may have been under-
estimated in the post-vaccination period. We show pregnancy
outcomes overall and stratified by vaccination period; data were
too spare for further statistical analysis.
Time at Risk
The follow-up period for this analysis spans from 24 January
2007, the first date a vaccination occurred, through 5 May 2009
when data were pulled for this analysis. The enrolment period
spanned from 24 January through 18 September 2007. Women
contributed person years from first vaccination to first pregnancy
defined as the last menstrual period plus 14 days, or the date of
her last visit within the follow-up timeframe noted above. For
women with multiple pregnancies (3 women had 2 pregnancies)
only the first pregnancy was counted.
Statistical Methods
To describe the enrolled sample, we calculated the frequency of
women’s demographic, contraceptive use, sexual behaviour and
risk profiles as measured at screening. Overall pregnancy
incidence is expressed per 100 women-years with an associated
95% confidence interval. Pregnancy incidence was stratified by
socio-demographics, behaviours, partner profile, and vaccination
period. Poisson regression was used to compare pregnancy rates
during and after the vaccination period. Cox proportional hazards
regression was used to assess predictors measured at screening with
time to first pregnancy, and to assess the role of contraceptive use
during the trial by allowing contraceptive use to be time varying.
Given the modest sample size and the need for parsimony during
model building, only contraceptive use was considered for the
time-varying analysis, and interaction terms to test for joint effects
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behavioural risk factors, pregnancy rates stratified by number of
risk behaviours (none or one versus two or more) were shown. A
priori considerations (both condom use measures) or variables with
p,0.20 in univariable analysis were considered for multivariable
modelling. Following adjustment, any variable with a p-value.0.2
was excluded from the model.
Results
Women (n=352) were predominantly young (median 23 years,
inter-quartile range (IQR) 20–27) and Black African 98.9%
(Table 1). At screening all reported intent to avoid pregnancy
during the vaccination period. About two thirds (68.8%) of women
were enrolled at a site that provided hormonal contraception. In
this analysis, women were followed for a median of 1.5 years (IQR
1.36–1.74), with minimum time at risk of 1 day (for one woman
found pregnant at her first vaccination follow up visit) to a
maximum of 2.24 years. For this analysis, retention was 100%,
89% and 85% at months 7, 12 and 18, respectively.
Sample Characteristics
At screening, most women (58.5%) self-reported use of
injectable contraception while 13.4% reported oral contraceptive
pill use (Table 1). Regarding condom use, using the derived
measure, 57.1% reported consistent condom use in the 6 months
prior to screening while 79.6% reported current use of male or
female condoms as measured by a single (yes/no) question. About
a quarter (28.1%) of women reported heavy drinking, marijuana
use, and/or use of these during sex or some combination of these
activities (Table 2). Heavy drinking accounted for most of these
high risk activities. Five percent of women reported a recent STI
diagnosis and most women (74.4%) had a single a main sex
partner at screening.
Pregnancy Rates and Outcomes by Vaccination Period
Of 51 total pregnancies, 48 first pregnancies occurred, or 13.6%
(48/352) of women became pregnant. Overall pregnancy
incidence was 9.6/100 w-yrs [48/501.1 w-yrs, 95% confidence
interval (CI) 7.22 –12.71]. Pregnancy incidence during and after
the vaccination period was 6.8 and 11.3/100 w-yrs, respectively;
RR 0.60 (95%CI: 0.32–1.14; p=0.10) (Table 3). Overall, half
(47%) of pregnancies resulted in a full-term live birth. The
distribution of other birth outcomes is shown in Table 3.
Baseline Associations with Pregnancy –Unadjusted
Pregnancy rates were lower among women using injectable
contraception at screening (hazard ratio [HR] 0.46, 95% CI 0.26
–0.81) (Table 1). Compared with women with a single partner of
HIV-unknown status, pregnancy rates were increased both among
women with a single partner known to be HIV-negative
[HR=2.03 (1.01–4.07)], and among women with 2 partners also
of unknown HIV status [HR=3.42 (1.26–9.25)] (Table 2).
Pregnancy rates tended to be higher among women reporting
sexually transmitted infections or a combination of two or more of
the following factors: marijuana use, heavy drinking or use of these
during sex, though confidence intervals were wide (Table 2).
Time-varying Associations with Pregnancy – Unadjusted
Pregnancy rates were reduced among women who reported
using injectable contraception during the trial [HR=0.41 (0.23–
0.71)] (Table 1). There was a similar protective trend among
women reporting consistent condom use during the trial
[HR=0.60 (0.34–1.07)], but not among women reporting
condom use when measured as a single, ‘‘yes/no’’ question
[HR=0.76 (0.41–1.41)]. Women reporting use of oral contracep-
tive pills (OCPs) during the trial had double the pregnancy
incidence of those not reporting such use [HR=2.02 (1.07–3.83)].
Multivariable Associations with Pregnancy
Pregnancy rates were reduced among women enrolled at a trial
site that provided hormonal contraception, who entered the study
as consistent condom users or as users of injectable contraceptives
(Table 4). Women who engaged in at least two different high risk
substance use behaviours such as heavy drinking, marijuana
smoking, or use of these substances during sex had double the
pregnancy incidence compared with women who did none of these
activities [HR=2.66 (1.24–5.72)]. Compared with women
reporting a single partner of unknown HIV status, pregnancy
rates were increased both among women with a single partner but
whose status was known to be HIV-negative [HR=2.34 (1.16–
4.73)] and among women with 2 partners also with unknown HIV
status [HR=4.42 (1.59–12.29)]. Considering all behavioural risk
factors identified (inconsistent condom use, non-use of injectable
contraceptives, and drug/alcohol use), pregnancy incidence was
7.1/100 w-yrs among women with none or only one such risk
factor and was 17. 4/100 w-yrs among women with at least two of
these risk factors, [HR=2.46 (1.39 –4.35), p=0.02].
Discussion
Overall the pregnancy rate was at the low end of the range
observed in other HIV prevention trials, on par with the one other
vaccine trial reporting on pregnancy incidence in sub-Saharan
Africa [10], and was half of that seen among African women
enrolled in non-trial cohorts [16,17]. Women in this trial were
largely able to adhere to their initial agreement to avoid becoming
pregnant during the vaccination period. Although the difference in
pregnancy rates during and after the vaccination period was not
statistically significant, there was a trend to higher rates after the
vaccination period. We expect that the true difference is even
greater since pregnancy testing in the post-vaccination period was
less rigorous and likely under estimated the true pregnancy rate.
The proportion of elective abortions appeared to be elevated for
pregnancies conceived during the vaccination period, compared
with those conceived later, although we cannot conclude this with
certainty because the study was not powered to evaluate this
finding. We do not have information on women’s motivations, but
a range of explanations for these elective terminations are possible.
These may include: more immediate access to the health care
system during trial participation; that women perceived it was
unsafe to conceive a pregnancy during the vaccination period as
they were advised to be on contraception during this time; or may
simply reflect that pregnancies in the post-vaccination period were
more often intended given women’s agreement to avoid them
during the vaccination period. We lack detail on the circumstances
of the elective abortions, but this procedure is legal in South
Africa. Regarding pregnancy outcomes, those observed here were
on par with another trial [7] and from a representative community
sample of South African women [18].
Encouraging was that predictive factors were identified, over-
and-above the requirement that women use at least two forms of
contraception as was required in this trial. All of the additional
factors can be readily measured during screening for a large
clinical trial, some are modifiable at trial entry, and preventive
measures were associated with at least a halving in pregnancy risk.
It is likely that the convenience, immediacy, certainty, and quality-
of-care associated with on-site injectable contraceptive access is
Pregnancy Incidence in an African Vaccine Trial
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another trial showing that women obtaining contraception off-site
were at increased pregnancy risk [10]. The pregnancy rates among
injectable contraception users was higher than that typically seen
for ‘‘perfect,’’ established users. It may reflect imperfect measure-
ment as these findings were based on self-report for an unspecified
timeframe of ‘‘current use’’ not clinical records, and thus may not
have adequately captured the exact duration of use. Alternatively,
women may not have been established users.
We also found that women who entered the trial using, and who
continued to use, injectable contraceptives, but not oral contra-
ceptive pills, were less likely to get pregnant. Despite being
counter-intuitive, this finding has also been observed elsewhere: in
a South African microbicide trial, pregnancy rates were 11.5/
100 w-yrs among oral contraceptive users and ,2.0/100 w-yrs
among women on injectables [13]. Even though both injectables
and the pill have high method-effectiveness, women’s ability to
consistently and/or correctly use the pill may diminish its method-
effectiveness, and result in lower use-effectiveness, which takes into
Table 1. Demographic characteristics and contraceptive use by incident pregnancy.
Column % (n)
Rate per 100 woman yrs (No.
pregnancies/woman yrs)
Unadjusted Rate Ratio
(95% CI) P-value
Overall pregnancy incidence (352) 9.6 (48/501) – –
Age in years 0.24
18–20 28.7 (101) 11.3 (16/142) 1
21–25 38.9 (137) 9.9 (19/192) 0.89 (0.46–1.72)
26–30 20.2 (71) 10.7 (11/103) 0.94 (0.44–2.03)
31–35 12.2 (43) 3.1 (2/64) 0.28 (0.06–1.23)
Race 0.53
Black 98.9 (348) 9.5 (47/496) 1
Mixed 1.1 (4) 19.4 (1/5) 2.05 (0.28–14.8)
Contraception supplied at site
Yes 68.8 (242) 8.3 (29/348) 0.68 (0.38–1.21)
No 31.3 (110) 12.4 (19/153) 1 0.20
Contraception use at screening
Consistent condom use in 6 months prior to screening
Yes 57.1 (201) 8.6 (25/290) 0.78 (0.44–1.38)
No 42.9 (151) 10.9 (23/211) 1 0.39
Any current male/female condom use
Yes 79.6 (280) 10.4 (42/403) 1.72 (0.73–4.05)
No 20.5 (72) 6.1 (6/98) 1 0.19
Current use of oral contraceptive pills
Yes 13.4 (47) 15.4 (10/65) 1.80 (0.90–3.62)
No 86.6 (305) 8.7 (38/436) 1 0.12
Current use of injectable contraceptive
Yes 58.5 (206) 6.4 (19/296) 0.46 (0.26–0.81)
No 41.5 (146) 14.2 (29/205) 1 0.007
Contraception use during follow up (time varying)
Consistent condom use
Yes –* 8.5 (26/328) 0.60 (0.34–1.07) 0.09
No 12.0 (22/173) 1
Any current male/female condom use
Yes –* 8.8 (33/375) 0.76 (0.41–1.41) 0.40
No 11.9 (15/126) 1
Use of oral contraceptive pills
Yes –* 16.7 (13/78) 2.02 (1.07–3.83) 0.04
No 8.3 (35/423) 1
Use of injectable contraceptive
Yes –* 6.6 (22/330) 0.41 (0.23–0.71) 0.002
No 15.5 (26/168) 1
*Data from multiple time points contribute to this statistic, number for each time point not shown.
doi:10.1371/journal.pone.0031387.t001
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contraceptives to increase pregnancy risk, and there are several
possible explanations for observing a positive association between
oral contraceptives and pregnancy. First, some women reporting
oral contraceptive use, may not have been using a legitimate
contraceptive, as there are pills in the marketplace that may not be
contraceptive, but are advertised or understood as such. Second,
as some form of hormonal contraception was required during the
trial, those not using oral contraceptives were therefore using
injectables, and the contrast between these two groups may simply
reflect the greater use-effectiveness of injectables. Alternatively,
when faced with the hormonal-method requirement, those opting
for oral contraceptives may reflect a group of women: ambivalent
about their pregnancy desires; not fully committed to avoiding
pregnancy who thus opted for a self-dosing method, or; committed
to avoiding pregnancy but who had difficulty adhering to the self-
dosing regimen required by oral contraceptives.
Regarding condoms, how use is measured is important for
distinguishing between casual and consistent users, as we found
that only the latter group was at lowered pregnancy risk. Condom
use measured via a single, ‘‘yes/no’’ question about ‘‘current’’ use,
was not predictive, while consistent condom use, derived from a
series of questions enquiring about condom use by each partner
type during a specified timeframe, showed a trend toward halving
pregnancy risk in the adjusted analysis. Careful measurements of
condom use to determine consistent use has also been shown as
protective by Reid et al., and use at last sex before study entry (but
as not as one’s main method) by Halpern et al. in trial settings.
Together these findings suggest that condoms may be a viable
method for pregnancy prevention, so long as they are used
consistently or recently. In contrast, if only a single, non-specific
Table 2. HIV risk indicators* at screening by incident pregnancy.
Column % (n)
Rate per 100 woman yrs (No.
pregnancies/woman yrs)
Unadjusted Rate Ratio
(95% CI) P-value
Overall pregnancy incidence (352) 9.6 (48/501) – –
Marijuana, heavy drinking
L and/or use of these during sex
$ 2 such activities 9.9 (35) 18.3 (9/49) 2.02 (0.96–4.23) 0.15
1 such activity 18.2 (64)
L 7.1 (7/99) 0.80 (0.35–1.81)
None 71.9 (253) 9.1 (32/253) 1
Diagnosed with sexually transmitted infection
Yes 5.1 (18) 20.8 (5/24) 2.38 (0.94–6.01) 0.10
No 95.9 (334) 9.0 (43/477) 1
Type of sex partner(s)
No partner 14.2 (50) 10.5 (7/67) 1.13 (0.50–2.56) 0.99
Causal only 2.3 (8) 10.3 (1/10 1.12 (0.15–8.19)
Main partner only 74.4 (262) 9.3 (35/375) 1
Main & casual partners 9.1 (32) 10.0 (5/50) 1.07 (0.42–2.74)
Main sex partner .10 yrs older
Yes 8.8 (26) 7.8 (3/38) 0.79 (0.24–2.57) 0.68
No 91.2 (268) 9.6 (37/386) 1
Living situation with main partner
Lives with main partner 45.5 (160) 9.0 (21/233) 1 0.92
Does not live with main partner 38.1 (134) 9.9 (19/192) 1.09 (0.59–2.03)
No main partner 16.5 (58) 10.5 (8/76) 1.17 (0.52–2.64)
Number of sexual partners
$2 partners 15.6 (55) 11.5 (9/78) 1.25 (0.60–2.58) 0.56
1 partner 84.4 (297) 9.2 (39/423) 1
Has partner of unknown HIV status
$1 partner(s)
& 48.9 (172) 8.4 (20/239) 0.78 (0.44–1.38) 0.39
No such partners (knows status) 51.1 (180) 10.7 (28/262) 1
Partner type by knowledge of HIV Status**
.2 partners varied knowledge 9.5 (33) 6.2 (3/48) 1.04 (0.29–3.72) 0.05
2 partners both unknown status 6.3 (22) 20.0 (6/30) 3.42 (1.26–9.25)
1 partner known negative 46.4 (162) 12.0 (28/234) 2.03 (1.01–4.07)
1 partner unknown status 37.8 (132) 6.0 (11/184) 1
*Refers to six months prior to screening interview.
LHeavy drinking defined as 5 or more alcoholic drinks in one day; 81% (52/64) of these women were heavy drinkers.
&Includes women with partners where HIV status was either all unknown, or status known for 1 of multiple partners.
**Excludes 3 women with known HIV-positive partners as data too scant for a separate stratum. No pregnancies occurred among these women.
doi:10.1371/journal.pone.0031387.t002
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condom use without further corroboration, (either in response to
additional questioning or by failing to demonstrate familiarity with
condoms when using a model) these women should be flagged as
those in need of more intensive pregnancy counselling and
support.
Pregnancy was also a function of HIV status, and number, of
partners. Using women with a single partner of unknown HIV
status as a reference, we were able to examine the unique impact
of HIV status alone (by comparing pregnancy rates of women with
only one partner with unknown status vs. negative HIV status) and
of multiple partners (by comparing the impact of 1 versus 2
partners among women who didn’t know their partners’ HIV
status). Regarding the former, knowing a sex partner’s HIV status
may be emerging as a partnership factor of interest. Not knowing a
partner’s HIV status may be a marker of a newer relationship
where HIV status has not yet been discussed and so women were
taking greater precautions against becoming pregnant. Alterna-
tively, it may reflect a relationship where HIV status cannot be
discussed, and thus women were hesitant to cement the
relationship further with a pregnancy. We were unable to test
these hypotheses as we lacked data on relationship duration and
disclosure. This finding deserves further research. Regarding
multiple partners, this may be a marker for women with more
risky behaviour in general, as multiple partnering is also a risk
factor for HIV. It is unclear whether the multiple partnering seen
here is due to commercial transactions, as almost no women
Table 3. Pregnancy incidence and outcomes by vaccination period.
Pregnancy rates Outcome of pregnancy* Row % (n)
Full-term
life birth
Premature
life birth
Fetal death/
still birth
Spontaneous
abortion
Ectopic
pregnancy
Elective
abortion
Overall rate per 100 w-yrs
9.6 (48/501)** 47 (20) 16 (7) 2 (1) 7 (3) 2 (1) 26 (11)
Rate during vaccination period
L
6.8 (13/191)** 23 (3) 23 (3) 0 8 (1) 0 46 (6)
Rate after vaccination period
11.3 (35/310)** 57 (17) 13 (4) 3 (1) 7 (2) 3 (1) 17 (5)
*Outcome of pregnancy not known for 5 women.
**Number of pregnancies/woman years.
LDefined as the period between a woman’s first scheduled vaccination through 1 month after the third, and final scheduled vaccination for that woman.
doi:10.1371/journal.pone.0031387.t003
Table 4. Multivariable model* of screening factors associated with incident pregnancy.
Unadjusted Rate Ratio Adjusted
L Rate Ratio (95% CI) p-value
Contraception supplied at site
Yes 0.68 0.43 (0.22–0.86) 0.02
No 1 1
Consistent condom use (in 6 months prior to screening)
Yes 0.78 0.54 (0.28–1.04) 0.07
No 1 1
Using injectable contraception at screening
Yes 0.46 0.37 (0.21–0.67) 0.0009
No 1 1
Marijuana use, heavy drinking** and/or use during sex (in 6 months prior to screening)
$ 2 such activities 2.02 2.66 (1.24–5.72) 0.05
1 such activity 0.80 0.85 (0.36–2.02)
None 1 1
Partner type by knowledge of HIV status (in 6 months. prior to screening)
.2 partners mixed knowledge of status 1.04 1.01 (0.27–3.74) 0.01
2 partners both unknown status 3.42 4.42 (1.59–12.29)
1 partner known negative 2.03 2.34 (1.16–4.73)
1 partner unknown status 1 1
*Final model does not include 3 women with known HIV-positive partners as this stratum was too thin for modeling.
LAdjusted for all other variables in the model; for variables with .2 levels the overall p value shown.
**Heavy drinking defined as 5 or more alcoholic drinks in one day.
doi:10.1371/journal.pone.0031387.t004
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not shown as it was extremely uncommon).
While almost twenty percent of the sample reported heavy
drinking, it was heavy drinking along with either marijuana use, or
concurrent drinking and sex that were associated with a two fold
risk of pregnancy. Heavy drinking and recreational drug use are
well-established risk factor for HIV in South Africa [19]. The
distinct nature of our finding requires corroboration, but
preliminary implications for clinical trialists are that women
reporting multiple risk factors, but not heavy drinking alone,
should be flagged for increased pregnancy prevention counselling,
and may be especially suitable candidates for trials given their
increased risk for HIV, and their need for the risk reduction
packages offered within trials. However, the larger public health
problem of alcohol use and pregnancy remains.
Strengths and Limitations
Strengthsofthisanalysisarethatitisthefirstreportfromavaccine
trial on risk factors for pregnancy and the longitudinal design with
high retention enhanced ability to make causal inferences. Factors
examined were all collected within the context of a typical clinical
trial,anddidn’trequirespecializedinterviewingtechniques,yetwere
highlypredictiveofpregnancyrisk.Thisbodeswellforfuturetrialsas
womencanbereadilyscreenedforpregnancyusingafewquestions.
Limitations of this analysis were the variable pregnancy prevention
messages and pregnancy outcome ascertainment once the trial was
interrupted. Nonetheless, we were still able to make valid compar-
isons within the dataset as the direction of the bias was known, but
giventhelackofsystematicpregnancytestinginthepost-vaccination
period, overall pregnancy ratesmay be underestimated.
Conclusion
It is possible to efficiently screen women for pregnancy risk, and
concrete steps such as providing injectable hormonal contraception
forfreeon-site,andsupportingconsistentcondomusers,canreduce
pregnancy risk among South African women in HIV trials.
Additionally, among women with a single partner, differential
knowledgeofmalepartners’HIVstatusimpactspregnancyratesand
is a new finding that deserves further research to illuminate the
underlying reason for its association with pregnancy. Given long-
standing calls to better integrate family planning and HIV/STI risk
reductioncounselling, clinicaltrialistsandhealthcounsellorsshould
make it a point to enquire about the number of, and male partner’s
HIV status as a potential modifier of pregnancy and HIV risk.
Together, these few simple steps may help to maximize the safety of
the mother and childrenconceived during HIVprevention trials.
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